ACON

Aclarion, Inc. (ACON) - Q3 2024 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended September 30, 2024. Aclarion, Inc. is a healthcare technology company leveraging magnetic resonance spectroscopy (MRS) and proprietary biomarkers to optimize clinical treatments. The company is classified as a non-accelerated filer, a smaller reporting company, and an emerging growth company. As of November 14, 2024, there were 10,431,159 shares of common stock outstanding.

Key Financial Metrics

Operating Cash Flow (9 Months): Net cash used in operating activities was $(4,348,748) for the nine months ended September 30, 2024, compared to $(2,913,165) in the prior year period.

Material Changes vs. Prior Period

• Revenue Decline: Revenue decreased 24% quarter-over-quarter and 42% year-over-year (9 months), primarily due to the conclusion of certain clinical activities at customer sites.
• Debt Elimination: Total liabilities dropped significantly from $3.19 million to $678,267. The company extinguished all Senior Notes payable through a combination of cash payments and debt-for-equity exchanges.
• Equity Position: Stockholders' equity turned positive ($2.51 million) from a deficit of $(728,000) at year-end 2023, driven by capital raises and the reclassification of debt to equity.
• Operating Expenses: Total operating expenses increased slightly in Q3 ($1.29M vs $1.16M) but decreased for the nine-month period ($3.68M vs $3.75M), largely due to reduced bonus accruals and personnel expenses.

Guidance, Outlook, Risks, and Unusual Items

• Liquidity and Going Concern: Management states that current cash ($1.32M) is sufficient to fund operations only through December 2024. The filing explicitly raises "substantial doubt" about the company's ability to continue as a going concern without additional financing.
• Nasdaq Compliance Risks:
  • Minimum Bid Price: The company failed to meet the $1.00 minimum bid price requirement. An appeal is pending, with an extension granted until January 31, 2025, to demonstrate compliance. A reverse stock split is planned.
  • Stockholders' Equity: The company received a delisting notice for failing to meet the $2.5 million stockholders' equity requirement. An appeal was granted an extension until January 31, 2025.
• Unusual Items:
  • Loss on Exchange of Debt: A significant non-cash charge of $1,073,317 was recorded in the nine months ended September 30, 2024, related to the exchange of debt for common stock and preferred stock.
  • Capital Raises: The company raised approximately $3.0 million via a public offering in February 2024, utilized an equity line of credit, and raised $1.0 million via Series C preferred stock in September 2024.
• Internal Controls: Management concluded that disclosure controls and procedures were not effective due to limited resources and a lack of segregation of duties.

Investor Verification Checklist

• Cash Runway: Verify the timeline for the next capital raise, as current funds are projected to last only until December 2024.
• Nasdaq Status: Monitor the outcome of the pending appeals regarding the minimum bid price and stockholders' equity requirements to assess delisting risk.
• Debt-for-Equity Terms: Review the conversion terms of the newly issued Series B and Series C preferred stock, including liquidation preferences and anti-dilution provisions.
• Revenue Sustainability: Assess the pipeline for new clinical contracts to replace the revenue lost from concluded customer site activities.
• Internal Control Remediation: Track progress on hiring or engaging external resources to address material weaknesses in financial reporting controls.